Loading…
Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor
The present study describes the cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV protease inhibitor currently in phase III clinical trials. BI 201335 showed a good Caco-II permeability (8.7 × 10−6 cm/sec) and in vitro metabolic stability (predicted h...
Saved in:
Published in: | Xenobiotica 2012-02, Vol.42 (2), p.164-172 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The present study describes the cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV protease inhibitor currently in phase III clinical trials.
BI 201335 showed a good Caco-II permeability (8.7 × 10−6 cm/sec) and in vitro metabolic stability (predicted hepatic clearence (CLhep) |
---|---|
ISSN: | 0049-8254 1366-5928 |
DOI: | 10.3109/00498254.2011.611546 |